Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Esophageal Squamous Cell Carcinoma 23Carcinoma, Hepatocellular 23Stomach Neoplasms 14Colorectal Neoplasms 13Liver Neoplasms 7Esophageal Neoplasms 6Rectal Neoplasms 5Pancreatic Neoplasms 4Cholangiocarcinoma 4Locally Advanced Rectal Cancer 3Biliary Tract Neoplasms 3Advanced Pancreatic Cancer 3Turcot syndrome 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Microsatellite Stable Metastatic Colorectal Cancer 2Klatskin Tumor 2Gallbladder Neoplasms 2Early Low Rectal Cancer 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of the Stomach 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Carcinoma of Esophagus 1Sarcoma 1Radiotherapy 1Pathologic Complete Response 1Pancreatic Cancer Metastatic 1

Interventions

Gemcitabine 61Cisplatin 39Oxaliplatin 31Capecitabine 29Fluorouracil 22Leucovorin 20Irinotecan 12pembrolizumab 11130-nm albumin-bound paclitaxel 10durvalumab 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Taxes 6Platinum 6Magnetic Resonance Spectroscopy 6Biopsy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Specimen Handling 5Sorafenib 5Radiotherapy 5Docetaxel 5Carboplatin 5Immunohistochemistry 4trifluridine tipiracil drug combination 3dehydroftorafur 3atezolizumab 3Watchful Waiting 3Tegafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × toripalimab × Gastrointestinal × Clear all
NCT06717464 2024-12-05

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Active not recruiting
110 enrolled
Gastrointestinal

Gallbladder Neoplasms, Klatskin Tumor

NCT04211168 2023-03-29

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Peking Union Medical College Hospital

Phase 2 Unknown
44 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡